AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32543677 — intervention group
Group type: COMPARATOR
Intervention: Generic reminders (general information about regional screening adherence)
Number of subjects: 0
Study 32543677 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no reminders)
Number of subjects: 0
Study 32064530 — intervention group
Group type: EXPERIMENTAL
Intervention: Generativity intervention (writing about life experiences and sharing advice with others)
Number of subjects: 73
Study 32064530 — intervention group
Group type: COMPARATOR
Intervention: Control condition (writing about neutral topics)
Number of subjects: 73
Study 33634488 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 0
Study 33634488 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation + Nature Sounds (PMR + NS)
Number of subjects: 0
Study 33634488 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine teaching procedure)
Number of subjects: 0
Study 35398870 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based psychosocial education and counseling program
Number of subjects: 55
Study 33431344 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week low energy diet (LED)
Number of subjects: 223
Study 33431344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-LED levels of IGF-II and IGF2R
Number of subjects: 223
Study 32928277 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention program (HEP-S) for 20 weeks
Number of subjects: 600
Study 32928277 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced online intervention program (HEP-S with gamification) for 20 weeks
Number of subjects: 600
Study 32928277 — intervention group
Group type: COMPARATOR
Intervention: Standard control group with no intervention
Number of subjects: 600
Study 35361442 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT exercise
Number of subjects: 80
Study 35361442 — intervention group
Group type: COMPARATOR
Intervention: n-3 FA supplementation
Number of subjects: 80
Study 35361442 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil 1.6 g daily)
Number of subjects: 80
Study 33250284 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐sided locking STS
Number of subjects: 24
Study 33250284 — intervention group
Group type: COMPARATOR
Intervention: Pulvertaft
Number of subjects: 24
Study 33250284 — intervention group
Group type: EXPERIMENTAL
Intervention: Double‐sided nonlocking STS
Number of subjects: 24
Study 35101083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 1 g intravenous bolus at the start and at the end of surgery
Number of subjects: 10000
Study 35101083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension-avoidance strategy
Number of subjects: 10000
Study 35101083 — intervention group
Group type: COMPARATOR
Intervention: Hypertension-avoidance strategy
Number of subjects: 10000
Study 33543867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex as primary reversal agent
Number of subjects: 419
Study 33543867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex exclusively
Number of subjects: 419
Study 33543867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex use among practitioners with ≤5 years of practice
Number of subjects: 419
Study 33543867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex use after controlling for institutional restriction and practice type
Number of subjects: 419
Study 33543867 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of NMB (train-of-four)
Number of subjects: 419
Study 33543867 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of NMB among anesthesiologists using sugammadex
Number of subjects: 419
Study 33543867 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of sugammadex for pediatric postmenarchal girls
Number of subjects: 419
Study 33543867 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of sugammadex effects on hormonal contraception
Number of subjects: 419
Study 32179258 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR-guided strategy
Number of subjects: 3830
Study 32179258 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided strategy
Number of subjects: 3830
Study 34924251 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise (AE)
Number of subjects: 30
Study 34924251 — intervention group
Group type: COMPARATOR
Intervention: Land-based Exercise (LBE)
Number of subjects: 30
Study 34267349 — intervention group
Group type: EXPERIMENTAL
Intervention: I-P-R-F vaccine
Number of subjects: 180
Study 34267349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 33031329 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 33031329 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 33310384 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect questioning technique
Number of subjects: 581
Study 33310384 — intervention group
Group type: COMPARATOR
Intervention: Direct questioning technique
Number of subjects: 581
Study 33009815 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.8 mg Neuropeptide Y (NPY)
Number of subjects: 30
Study 33009815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 36328045 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine change of gloves and instruments before wound closure
Number of subjects: 13301
Study 36328045 — intervention group
Group type: COMPARATOR
Intervention: Current practice (no routine change of gloves and instruments)
Number of subjects: 13301
Study 34297114 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived concept of sexual harassment (touching body)
Number of subjects: 976
Study 34297114 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived uncomfortable behaviors by the assault
Number of subjects: 976
Study 34297114 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of sexual harassment among urban students
Number of subjects: 976
Study 34297114 — intervention group
Group type: COMPARATOR
Intervention: Frequency of sexual harassment among rural students
Number of subjects: 976
Study 34297114 — intervention group
Group type: EXPERIMENTAL
Intervention: Main motives for harassment (absence of sanctions)
Number of subjects: 976
Study 34297114 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for harassment (absence of punishment)
Number of subjects: 976
Study 34297114 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for harassment (wrong concepts about women)
Number of subjects: 976
Study 34297114 — intervention group
Group type: EXPERIMENTAL
Intervention: Main reaction to harassment (feeling bad and wishing to act)
Number of subjects: 976
Study 34297114 — intervention group
Group type: EXPERIMENTAL
Intervention: Main reaction to harassment (feeling bad but helpless)
Number of subjects: 976
Study 34297114 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported taking proper action against harassment
Number of subjects: 976
Study 34297114 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of harassment (urban students)
Number of subjects: 976
Study 34297114 — intervention group
Group type: COMPARATOR
Intervention: Experience of harassment (rural students)
Number of subjects: 976
Study 33980168 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly befriending for 4 months from a trained volunteer
Number of subjects: 0
Study 33980168 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 32379383 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Sleep (6.5 hr sleep opportunity)
Number of subjects: 88
Study 32379383 — intervention group
Group type: COMPARATOR
Intervention: Healthy Sleep (9.5 hr sleep opportunity)
Number of subjects: 88
Study 32295605 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Diet Replacement (TDR) programme
Number of subjects: 272
Study 35355200 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted incisional hernia repair (RVIHR)
Number of subjects: 37
Study 35355200 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic incisional hernia repair (LVIHR)
Number of subjects: 37
Study 33908635 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole, a benzothiazole sodium channel blocker, dosage and duration not specified.
Number of subjects: 0
Study 33908635 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model for riluzole incorporating time‐dependent clearance and volume of distribution.
Number of subjects: 0
Study 32708292 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 80
Study 32708292 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 80
Study 32708292 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 80
Study 32708292 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 80
Study 32708292 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Dabigatran, Rivaroxaban, Apixaban, Warfarin)
Number of subjects: 80
Study 32708292 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori presence
Number of subjects: 80
Study 32708292 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) use
Number of subjects: 80
Study 36244997 — intervention group
Group type: EXPERIMENTAL
Intervention: Glar/Exenatide
Number of subjects: 102
Study 36244997 — intervention group
Group type: EXPERIMENTAL
Intervention: Glar/Lispro
Number of subjects: 102
Study 36244997 — intervention group
Group type: EXPERIMENTAL
Intervention: Glar
Number of subjects: 102
Study 33720350 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 200 mg once daily for 7 days
Number of subjects: 726
Study 33720350 — intervention group
Group type: COMPARATOR
Intervention: Linezolid 600 mg every 12 hours for 10 days
Number of subjects: 726
Study 32344841 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 8 hour shifts
Number of subjects: 0
Study 32344841 — intervention group
Group type: EXPERIMENTAL
Intervention: Being a duty officer
Number of subjects: 0
Study 32344841 — intervention group
Group type: EXPERIMENTAL
Intervention: Not working the day before the accident
Number of subjects: 0
Study 32344841 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance between home and work >3.6 to 9 km
Number of subjects: 0
Study 32344841 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance between home and work >9 km to 19 km
Number of subjects: 0
Study 32344841 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance between home and work >19 km
Number of subjects: 0
Study 36397349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 36397349 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60
Study 36397349 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 32223724 — intervention group
Group type: EXPERIMENTAL
Intervention: Zephyr Valve
Number of subjects: 190
Study 32223724 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 190
Study 35138505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (SV)
Number of subjects: 143
Study 35138505 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (V)
Number of subjects: 143
Study 33225399 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus casei Zhang, Lactobacillus plantarum P‐8, and Bifdobacterium animalis subsp. lactis V9) for 28 days
Number of subjects: 45
Study 33225399 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine regimen without probiotics)
Number of subjects: 45
Study 36432479 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidified milk
Number of subjects: 14
Study 36432479 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 14
Study 36432479 — intervention group
Group type: COMPARATOR
Intervention: Non-dairy meal
Number of subjects: 14
Study 36432479 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fermentation
Number of subjects: 14
Study 36432479 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk and yogurt
Number of subjects: 14
Study 36432479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 14
Study 32917410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 3 mg/kg intravenously every 2 weeks for 48 weeks (monotherapy cohort)
Number of subjects: 20
Study 32917410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 3 mg/kg intravenously every 2 weeks for 48 weeks with hypofractionated radiation therapy (hfRT) during week 2 (combination cohort)
Number of subjects: 20
Study 32917410 — intervention group
Group type: COMPARATOR
Intervention: PD-L1 protein expression
Number of subjects: 20
Study 32917410 — intervention group
Group type: COMPARATOR
Intervention: PD-L1 mRNA levels
Number of subjects: 20
Study 35675940 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine injection after PRF ablation
Number of subjects: 73
Study 35675940 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection after PRF ablation
Number of subjects: 73
Study 33159822 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMBA I VL testing
Number of subjects: 60889
Study 36102962 — intervention group
Group type: EXPERIMENTAL
Intervention: C4d-positive group
Number of subjects: 65
Study 36102962 — intervention group
Group type: COMPARATOR
Intervention: C4d-negative group
Number of subjects: 65
Study 34664294 — intervention group
Group type: EXPERIMENTAL
Intervention: delmopinol
Number of subjects: 89
Study 34664294 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorhexidine (CHX)
Number of subjects: 89
Study 34664294 — intervention group
Group type: COMPARATOR
Intervention: placebo mouthrinse
Number of subjects: 89
Study 35908869 — intervention group
Group type: EXPERIMENTAL
Intervention: V114 (15-valent pneumococcal conjugate vaccine)
Number of subjects: 245
Study 35908869 — intervention group
Group type: COMPARATOR
Intervention: PCV13 (13-valent pneumococcal conjugate vaccine)
Number of subjects: 245
Study 36175271 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Number of subjects: 170
Study 36175271 — intervention group
Group type: COMPARATOR
Intervention: Health and Wellness Education (HEW)
Number of subjects: 170
Study 36175271 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TCC and HEW
Number of subjects: 170
Study 33588808 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month distance-learning curriculum adapted from Cooking Matters®
Number of subjects: 165
Study 32690521 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom foot orthoses made using a direct adaptation technique
Number of subjects: 0
Study 32690521 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom foot orthoses made through a digital design and production process
Number of subjects: 0
Study 32690521 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated orthoses
Number of subjects: 0
Study 32690521 — intervention group
Group type: COMPARATOR
Intervention: All interventions (custom FO and prefabricated orthoses)
Number of subjects: 0
Study 35337692 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole-palbociclib
Number of subjects: 106
Study 35337692 — intervention group
Group type: COMPARATOR
Intervention: Control (chemotherapy)
Number of subjects: 106
Study 33605108 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma with Tocilizumab (CPT)
Number of subjects: 110
Study 33605108 — intervention group
Group type: COMPARATOR
Intervention: Convalescent Plasma (CP)
Number of subjects: 110
Study 33172094 — intervention group
Group type: EXPERIMENTAL
Intervention: Foodbot Factory
Number of subjects: 73
Study 33172094 — intervention group
Group type: COMPARATOR
Intervention: Control app
Number of subjects: 73
Study 33991341 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg (weeks 0, 4, and 16)
Number of subjects: 120
Study 33991341 — intervention group
Group type: COMPARATOR
Intervention: Fumaric acid esters (FAEs) (30 mg daily up to 720 mg daily)
Number of subjects: 120
Study 34678593 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone treatment
Number of subjects: 0
Study 33423762 — intervention group
Group type: EXPERIMENTAL
Intervention: Quilting sutures
Number of subjects: 76
Study 33423762 — intervention group
Group type: COMPARATOR
Intervention: Sponge nasal packing
Number of subjects: 76
Study 32086016 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidized pour-flush latrine to septic tank system
Number of subjects: 517
Study 32086016 — intervention group
Group type: COMPARATOR
Intervention: Control compounds (existing shared latrines)
Number of subjects: 517
Study 32086016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention compounds (hygienic emptying)
Number of subjects: 517
Study 32985280 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (500 mg daily for 10 weeks)
Number of subjects: 52
Study 32985280 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 10 weeks)
Number of subjects: 52
Study 32926760 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent treatment (RT delivered on the same day as or in between doses of ICT)
Number of subjects: 199
Study 32926760 — intervention group
Group type: COMPARATOR
Intervention: Nonconcurrent treatment (RT not delivered on the same day as ICT)
Number of subjects: 199
Study 32926760 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent treatment
Number of subjects: 199
Study 33859685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.4 mg/kg continuous infusion over 20 min)
Number of subjects: 60
Study 33859685 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60
Study 34280047 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional computed tomography tutorial
Number of subjects: 0
Study 34280047 — intervention group
Group type: COMPARATOR
Intervention: 2-dimensional computed tomography tutorial
Number of subjects: 0
Study 32220072 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologically defined sarcopenia
Number of subjects: 2181
Study 34333487 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear Speech (CS)
Number of subjects: 31
Study 34333487 — intervention group
Group type: COMPARATOR
Intervention: Habitual Speech (HS)
Number of subjects: 31
Study 33151438 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching at 120% intensity
Number of subjects: 23
Study 33151438 — intervention group
Group type: COMPARATOR
Intervention: Static stretching at 100% intensity
Number of subjects: 23
Study 33151438 — intervention group
Group type: COMPARATOR
Intervention: Both groups (100% and 120% intensity)
Number of subjects: 23
Study 35474116 — intervention group
Group type: EXPERIMENTAL
Intervention: Workout on Wheels internet intervention (WOWii)
Number of subjects: 168
Study 35474116 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 168
Study 33882059 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwifery continuity of care (POPPIE group)
Number of subjects: 334
Study 33882059 — intervention group
Group type: COMPARATOR
Intervention: Standard maternity care (Control group)
Number of subjects: 334
Study 35140781 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA TI stimulation for 20 minutes
Number of subjects: 40
Study 35140781 — intervention group
Group type: COMPARATOR
Intervention: tDCS for 20 minutes
Number of subjects: 40
Study 33744981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab (IVB)
Number of subjects: 26
Study 33744981 — intervention group
Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 26
Study 32432388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorecivivint 0.07 mg
Number of subjects: 455
Study 32432388 — intervention group
Group type: COMPARATOR
Intervention: Lorecivivint 0.03 mg
Number of subjects: 455
Study 32432388 — intervention group
Group type: COMPARATOR
Intervention: Lorecivivint 0.23 mg
Number of subjects: 455
Study 32432388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study 36386125 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinbao pill (XBP)
Number of subjects: 284
Study 36386125 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug therapy combined with placebo
Number of subjects: 284
Study 34959963 — intervention group
Group type: EXPERIMENTAL
Intervention: Goji berries (28 g, five times weekly for 90 days)
Number of subjects: 27
Study 34959963 — intervention group
Group type: COMPARATOR
Intervention: Control group (supplement containing 6 mg L and 4 mg Z, five times weekly for 90 days)
Number of subjects: 27
Study 33408472 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 166
Study 33408472 — intervention group
Group type: COMPARATOR
Intervention: Severe exacerbation
Number of subjects: 166
Study 33983449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic cycling (IDC) - 6-month programme, thrice weekly, moderate intensity cycling (RPE 12-14)
Number of subjects: 92
Study 33983449 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (control group)
Number of subjects: 92
Study 33983449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic cycling (IDC)
Number of subjects: 92
Study 33983449 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of physical activity and fitness
Number of subjects: 92
Study 33541040 — intervention group
Group type: EXPERIMENTAL
Intervention: VR augmented RAGT
Number of subjects: 30
Study 33541040 — intervention group
Group type: COMPARATOR
Intervention: RAGT only
Number of subjects: 30
Study 35224215 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal washing with 20 cc of normal saline 0.9% before Misoprostol insertion
Number of subjects: 148
Study 35224215 — intervention group
Group type: COMPARATOR
Intervention: Control group (without vaginal washing)
Number of subjects: 148
Study 33176826 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated natural mushroom-derived vitamin D2 (25 μg or 1000 IU)
Number of subjects: 28
Study 33176826 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched-dose encapsulated vitamin D3 (25 μg or 1000 IU)
Number of subjects: 28
Study 33176826 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 28
Study 35288397 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg empagliflozin for 14 days
Number of subjects: 46
Study 35288397 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 14 days
Number of subjects: 46